What interviewers actually evaluate

Viatris marketing interviews test whether candidates understand how marketing complex generics and off-patent branded pharmaceuticals differs from branded pharma or consumer product marketing – where FDA's prescription drug advertising regulations under 21 CFR Part 202 prohibit promotional communications that make unapproved claims, omit fair balance risk information, or promote products for off-label uses in ways that create regulatory exposure and potential FDA Warning Letters that damage brand credibility with healthcare providers, where EpiPen's pricing history created a reputational context that marketing messaging about patient access and affordability must address authentically rather than defensively, and where marketing branded off-patent products in international emerging markets requires building physician and patient awareness for products competing on brand reputation against generic manufacturers who offer the same active ingredient at lower cost. Marketing at Viatris spans healthcare provider promotional marketing within FDA regulatory constraints (where sales force detailing messages, branded speaker programs, and direct-to-healthcare-provider advertising must comply with FDA's fair balance requirements and off-label promotion prohibition while still creating the product awareness and prescriber confidence that justify branded product promotional investment when generic alternatives are available at lower cost), DTC marketing for branded consumer-recognized products (where EpiPen's brand awareness among allergy patients and parents creates a DTC marketing opportunity that must be balanced against the fair balance requirements of DTC prescription drug advertising under FDA Guidance and the public sensitivity about EpiPen's pricing history), disease awareness and unbranded marketing programs (where Viatris can promote understanding of COPD, allergic rhinitis, or anaphylaxis risk without referencing specific products as a way of building the disease awareness that creates demand in therapeutic categories where Viatris's branded products compete), and international market brand building for off-patent branded products (where Viatris's Norvasc, Celebrex, and Lyrica branded positions in emerging markets compete against generic manufacturers who offer identical active ingredients without the brand investment, requiring marketing programs that differentiate on brand trust, consistent product quality, and physician familiarity rather than clinical innovation).

Start your free Viatris Marketing practice session.

What interviewers actually evaluate

FDA Promotional Compliance, Brand Reputation Management, and HCP Marketing Effectiveness

Viatris marketing interviews probe whether candidates understand how pharmaceutical marketing differs from consumer brand or technology marketing in the FDA promotional regulatory framework (the distinction between what a pharmaceutical marketer can say versus what is prohibited by FDA's regulations is not always intuitive – where a journal ad claiming EpiPen is "the leading epinephrine auto-injector" requires substantiation, where a speaker program slide that includes a case study from a clinical presentation that was not part of the approved labeling requires medical affairs review, and where a sales representative's response to an HCP's question about an off-label use must follow the medical information exchange protocol rather than the promotional framework – creating a marketing compliance obligation that does not exist in consumer categories), the EpiPen reputation management challenge (marketing EpiPen in a post-pricing-controversy environment requires messaging that acknowledges the affordability concern that the pricing history created for patients and payers while positioning Viatris as a committed access partner through patient assistance programs and the generic EpiPen option – where marketing that ignores the pricing history creates credibility risk with payers who remember the congressional scrutiny and with advocacy organizations that continue to monitor EpiPen pricing), and the branded versus generic product marketing investment trade-off (Viatris's portfolio includes both branded products that justify promotional investment to maintain prescriber preference and generic products that compete primarily on price and supply reliability without brand marketing – where marketing leaders must make portfolio-level investment decisions about which products merit branded promotional spend versus generic products that are best marketed through pricing strategy and distribution relationships rather than HCP detailing campaigns).

The international market brand building dimension creates a marketing challenge specific to Viatris's former Upjohn portfolio: in emerging markets where physician prescription patterns are influenced by brand familiarity and trust developed over decades of Pfizer brand association, Viatris must maintain the credibility of brands like Norvasc and Celebrex in markets where the Pfizer association historically provided brand assurance – now requiring Viatris brand-building investment to maintain the physician confidence that justified branded product pricing premiums over local generic alternatives.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
FDA prescription drug advertising compliance and fair balance integration	Do you understand how to develop compliant promotional materials for Viatris branded products – how to structure the fair balance risk information in a branded print advertisement for EpiPen that satisfies FDA's requirement for adequate presentation of risks alongside the product's benefits without creating a layout where the risk section dominates the visual space that limits the ad's promotional effectiveness, what the review process is for new promotional materials that ensures medical, legal, and regulatory review approval before materials are used with healthcare providers, and how to respond when an FDA Division of Drug Marketing, Advertising, and Communications letter alleges that a previously approved promotional piece omitted risk information that should have been included? We flag marketing answers that describe pharmaceutical marketing as creative brand development without engaging with the FDA promotional compliance review process and fair balance requirements that govern every piece of promotional communication.	Fair balance presentation standards, DDMAC promotional review process, FDA enforcement response
EpiPen brand reputation and patient access messaging strategy	Can you describe how to develop the EpiPen marketing messaging strategy that authentically addresses the pricing controversy legacy while positioning Viatris as a patient access partner – what the message framework is for payer audiences who remember the congressional testimony and are skeptical about Viatris's patient access commitment, how to present Viatris's patient assistance programs and generic EpiPen option to physicians who are aware of patients struggling with EpiPen cost, and what the DTC messaging strategy is for parents of anaphylaxis-risk children who have heard about EpiPen's price history and may be asking their physician about alternative devices? We score whether your EpiPen messaging approach engages with the specific credibility challenge that the pricing history created with payers, prescribers, and patients rather than treating EpiPen as a standard branded pharmaceutical requiring standard DTC and HCP marketing.	Payer credibility messaging, prescriber patient access conversation support, DTC fair balance with pricing context
Healthcare provider detail aid and speaker program development	Do you understand how to develop HCP promotional materials and speaker bureau programs for Viatris branded products – how to write a Dymista detail aid that differentiates the azelastine/fluticasone combination from monotherapy with either component for allergic rhinitis HCPs who are choosing between combination and sequential monotherapy, what the speaker bureau program design requires for compliance with the Sunshine Act disclosure requirements that apply to speaker honoraria paid to physician speakers, and how to measure detail aid effectiveness through prescription data trends and physician profiling that assess whether promotional investment is changing HCP behavior in the intended target audience? We detect marketing answers that describe HCP promotion as standard B2B marketing without engaging with the Sunshine Act speaker disclosure requirements and detail aid regulatory review process that distinguish pharmaceutical HCP marketing from other professional B2B marketing.	Detail aid differentiation message, speaker bureau Sunshine Act compliance, HCP promotional ROI measurement
International branded generic marketing and physician confidence building	Can you describe how to develop the marketing strategy for Viatris's Norvasc brand in a Southeast Asian market where the amlodipine active ingredient is available from 15 local generic manufacturers at prices 60-70% below Norvasc's WAC – what the physician messaging is that differentiates Norvasc's consistent formulation quality and manufacturing standards from generic alternatives in a market where physician concerns about generic quality variability create branded product preference at higher price points, how to measure the ROI of branded HCP detailing against the price premium Norvasc can sustain in the market, and what the patient-level marketing strategy is for branded Norvasc in a hypertension management market where physicians often recommend switching to generic amlodipine once blood pressure control is established? We flag marketing answers that treat branded generic marketing as equivalent to innovator branded pharmaceutical marketing without engaging with the quality differentiation and physician confidence messaging that makes branded generic premiums sustainable in price-sensitive markets.	Generic quality differentiation messaging, branded generic price premium sustainability, physician detailing ROI in generic-competitive markets

How a session works

Step 1: Choose a Viatris marketing scenario – FDA prescription drug advertising compliance and promotional material development, EpiPen brand reputation and patient access messaging strategy, HCP detail aid and speaker bureau program development, or international branded generic marketing and physician confidence building.

Step 2: The AI interviewer asks realistic Viatris-style questions: how you would respond when Viatris's EpiPen sales force reports that physicians are increasingly recommending Auvi-Q (the Kaleo epinephrine auto-injector) over EpiPen because of Auvi-Q's voice instruction feature and more compact design – including how to evaluate whether a clinical study comparing user errors between Auvi-Q and EpiPen represents fair and balanced scientific information that can be shared by the sales force, what the promotional message framework is for EpiPen's device reliability and established prescriber familiarity that can be communicated without making comparative claims that require substantiation, and how to develop the market research insight that determines whether device preference or access and pricing concerns are the primary driver of the prescribing shift; how you would develop the launch marketing plan for a supplemental NDA approval that extends EpiPen's FDA-approved indication to include dosing guidance for pediatric patients in a lower weight range than the current approved labeling covers – including what the HCP target audience segmentation is for the new pediatric indication, how to develop the fair balance presentation for a DTC digital marketing campaign targeting parents of at-risk children, and what the access strategy messaging is for payers who will need to update formulary coverage policies for the new indication; or how you would structure the physician marketing strategy for Dymista in a market where most allergists have established prescribing habits with generic fluticasone nasal spray supplemented by oral antihistamine, and where Dymista's combination formulation provides equivalent efficacy to the two-product regimen in a single device that improves patient compliance – including what the messaging framework is for demonstrating compliance advantage, how to develop the physician education program that quantifies the compliance benefit in allergic rhinitis symptom control outcomes, and what the managed care messaging strategy is for Dymista's formulary access relative to generic component alternatives.

Step 3: You respond as you would in the actual interview. The system scores your answer on FDA promotional compliance, EpiPen reputation messaging, HCP marketing program design, and international branded generic strategy.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical marketing expertise and what needs stronger FDA regulatory compliance specificity or branded generic differentiation analysis.

Frequently Asked Questions

What FDA regulations govern prescription drug advertising and promotion?
FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC, now OPDP) regulates prescription drug advertising and promotion under 21 CFR Part 202 and the FDCA's false advertising provisions. The regulations require that promotional materials be truthful and non-misleading, present fair balance between a product's benefits and risks, and not promote products for uses not approved in the FDA-approved labeling. For prescription drug advertising directed to consumers (DTC), FDA requires that broadcast advertisements present the most important risks in the audio or audio and visual portions of the advertisement. For promotional materials directed to healthcare providers, fair balance requires a presentation of risk information that gives appropriate prominence to the risks. FDA can issue Untitled Letters for minor promotional violations and Warning Letters for more serious promotional compliance failures, and both are publicly posted on FDA's website creating reputational as well as regulatory consequences.

How does the Sunshine Act affect Viatris's HCP marketing programs?
The Physician Payments Sunshine Act, enacted as part of the Affordable Care Act, requires pharmaceutical manufacturers to report annually to CMS all payments and transfers of value made to physicians and teaching hospitals above a de minimis threshold. For Viatris's HCP marketing programs, the reporting requirement applies to payments for consulting services, speaker bureau honoraria, meals provided during a sales detail, and research grants. The reported payments are publicly disclosed in CMS's Open Payments database, where physicians, patients, and advocacy organizations can look up what payments any physician has received from pharmaceutical companies. The transparency requirement changes the risk calculus for speaker bureau programs because physicians who receive speaker fees are identifiable, and physicians who are perceived as heavily compensated promotional speakers may face scrutiny from employer compliance programs or from patients who become aware of the payment relationship.

What is the Dymista product and what is its market positioning?
Dymista is an intranasal combination product that contains azelastine hydrochloride (an antihistamine) and fluticasone propionate (a corticosteroid) in a single nasal spray. FDA approved Dymista for the relief of symptoms of seasonal allergic rhinitis in patients 6 years and older for whom treatment with an antihistamine alone or intranasal corticosteroid alone is not considered adequate. Viatris markets Dymista as providing relief of both nasal and ocular allergic rhinitis symptoms in a single product that provides faster onset of action than either component alone for the combined allergic rhinitis symptom complex. The marketing challenge for Dymista is demonstrating a clinical and compliance advantage that justifies its cost relative to the combination of a generic antihistamine nasal spray and generic fluticasone – where payer formulary access requires evidence of clinical differentiation beyond convenience.

How does Viatris approach marketing in international markets where Pfizer previously owned the brands?
In markets where Viatris's former Upjohn brands were previously marketed under the Pfizer umbrella, transitioning brand ownership to Viatris required marketing communications to maintain physician and patient confidence while introducing the new Viatris brand identity. Physicians in markets like China, Russia, and Southeast Asia had decades of experience prescribing Norvasc, Celebrex, and other brands associated with Pfizer's quality standards and global regulatory compliance, and the marketing transition required messages that affirmed Viatris's commitment to the same manufacturing quality and regulatory compliance that physicians associated with the previous Pfizer ownership. The transition also required international regulatory filings to update the marketing authorization holder in each country where the brand is registered, a process that takes varying amounts of time across regulatory agencies and that requires marketing to manage the period when brand ownership has transferred commercially but regulatory documentation still reflects the prior holder.

What is Viatris's patient access marketing strategy for branded products?
Viatris's patient access marketing addresses the reality that many of Viatris's branded products – including EpiPen – face payer pressure to substitute less expensive alternatives including generic products that contain identical active ingredients. Patient access marketing for EpiPen includes promoting Viatris's patient assistance programs to physicians and pharmacists who serve patients with limited insurance coverage, communicating the availability of the generic EpiPen (marketed by Viatris at a lower list price) as an access alternative, and providing training materials that support prior authorization appeal processes for patients denied coverage at their commercial plan's formulary tier. The patient access messaging must be carefully differentiated from branded product promotional messaging to avoid creating the appearance that Viatris is using patient access as a disguised promotional strategy for maintaining brand loyalty rather than genuinely addressing affordability concerns.